Amicus Therapeutics, Inc.
FOLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $528 | $399 | $329 | $306 |
| % Growth | 32.3% | 21.3% | 7.8% | – |
| Cost of Goods Sold | $53 | $37 | $39 | $34 |
| Gross Profit | $475 | $362 | $291 | $271 |
| % Margin | 90% | 90.7% | 88.3% | 88.7% |
| R&D Expenses | $109 | $152 | $277 | $272 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $323 | $275 | $213 | $193 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $18 | $12 | $13 | $13 |
| Operating Expenses | $450 | $439 | $503 | $477 |
| Operating Income | $25 | -$77 | -$212 | -$206 |
| % Margin | 4.7% | -19.3% | -64.4% | -67.6% |
| Other Income/Exp. Net | -$54 | -$73 | -$30 | -$35 |
| Pre-Tax Income | -$29 | -$150 | -$242 | -$242 |
| Tax Expense | $27 | $1 | -$5 | $9 |
| Net Income | -$56 | -$152 | -$237 | -$250 |
| % Margin | -10.6% | -38% | -71.9% | -82% |
| EPS | -0.18 | -0.51 | -0.82 | -0.92 |
| % Growth | 64.7% | 37.8% | 10.9% | – |
| EPS Diluted | -0.18 | -0.51 | -0.82 | -0.92 |
| Weighted Avg Shares Out | 304 | 295 | 289 | 271 |
| Weighted Avg Shares Out Dil | 304 | 295 | 289 | 271 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $7 | $3 | $1 |
| Interest Expense | $50 | $50 | $37 | $32 |
| Depreciation & Amortization | $9 | $8 | $5 | $6 |
| EBITDA | $29 | -$92 | -$200 | -$203 |
| % Margin | 5.6% | -23.1% | -60.6% | -66.4% |